Core Insights - Ascletis Pharma Inc. has selected ASC36, an oral amylin receptor peptide agonist, for clinical development targeting obesity, with an Investigational New Drug Application (IND) submission to the FDA expected in Q2 2026 [1] Group 1: Drug Development and Efficacy - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% in non-human primate studies, with a long elimination half-life of 116 to 167 hours, supporting once-daily dosing [1] - In non-human primates, ASC36 reduced mean body weight by up to 13.2% from baseline after 7 days of once-daily dosing and significantly reduced food intake [1] - In a diet-induced obese rat model, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively [1] Group 2: Technological Advancements - ASC36 was developed using Ascletis' proprietary Peptide Oral Transport Enhancement Technology (POTENT) and Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) [1] - The expected lower dosing of ASC36 compared to recently FDA-approved oral GLP-1R peptide agonists may provide scalability advantages in manufacturing [1] Group 3: Company Overview - Ascletis Pharma Inc. is a fully integrated biotechnology company focused on developing therapeutics for metabolic diseases, utilizing multiple proprietary technology platforms [1] - The company has a diverse pipeline portfolio, including ASC30, a small molecule GLP-1R agonist, and other peptide agonists for chronic weight management [1]